Molecular Tumor Board Series - Stage II CRC - KRAS codon A146T, ATM codon R1898 mutations
CIRCULOGENE Molecular Tumor Board Series Stage II CRC – liquid biopsy KRAS codon A146T, ATM codon R1898 mutations with no tissue confirmation Determination - No easy or effective therapy based upon detailed – with a peace of mind Discussion why Time Matters - 4 week delay increases mortality Target is 30 days from diagnosis to treatment
▶︎
Molecular Tumor Board - Metastatic melanoma with CDKN2A and PD-L1
▶︎
Molecular Tumor Board Series - Breast Cancer with ESR1 and PIK3CA mutations
▶︎
William Davis - Bowels Gone Wild: Microbiome Strategies For Age-Reversal
▶︎
Blood Transfusion in Acute Coronary Syndromes: The Evidence Behind the 2025 CCS/NAC Joint Statement
▶︎
AJ Styles On Retirement, Gunther, Hall Of Fame, John Cena, One More Match?
▶︎
Chichvarkin Saves Putin | Vitaly Portnikov
▶︎
Is It Really Impossible To Pull Apart Two Interleaved Phone Books? | MythBusters
▶︎
Molecular Tumor Board - SMARCA4 mutation in Lung Cancer
▶︎
Colin Champ: Fighting Cancer with Food and Fitness
▶︎
We Bought Temu's Craziest Product!!!
▶︎
Inflation, Deficits, Interest Rates: Warning, Immediate Danger!
▶︎
Duane Mitchell - Advancing Immunotherapy for Malignant Brain Tumors
▶︎
Geopolitical Portrait of Belarus
▶︎
Clinical utility of Liquid Biopsy for patient response and cancer progression.
▶︎
Chris Logothetis - Addressing Paradoxes in Health Care
▶︎
First words as head coach: Klopp issues a clear warning!
▶︎
Kurt Eicholz, MD, discusses MIS: Outpatient vs ASC at #DSPN #spinesummit 2026
▶︎
Pimicotinib in Tenosynovial Giant Cell Tumor (TGCT)
▶︎
Worst Plane Landing Fails Caught on Camera
▶︎